Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need. Safety and efficacy of the following compounds have not been established.

Gilead has helped transform HIV infection from a fatal and debilitating disease into a chronic, manageable condition. Yet new options are needed to improve treatment and care over the course of a lifetime for diverse populations living with HIV around the world. With two million new infections each year, additional prevention options are also needed. And ultimately, a cure is needed to bring an end to the HIV epidemic.

Gilead is committed to the continued discovery and development of HIV therapies for all individuals who live with the disease, regardless of treatment status or age. Our research is focused on the three paradigms: prevention, treatment and cure.

HIV / AIDS

Phase 1
Phase 2
Phase 3

B/F/TAF
Potential Indication: HIV/AIDS

US and EU Regulatory Submission

Descovy
Potential Indication: PrEP

GS-9620 (TLR-7 agonist)
Potential Indication: HIV/AIDS

GS-9722 (bNab)
Potential Indication: HIV/AIDS

Gilead R&D has helped transform the treatment of chronic hepatitis C infection and help manage chronic hepatitis B infection. Today, the company’s liver disease research focuses on medicines for nonalcoholic steatohepatitis (NASH) in patients with advanced fibrosis and on the long-term suppression of hepatitis B virus.

Liver Diseases

Phase 1
Phase 2
Phase 3

GS-9688 (TLR-8 agonist)
Potential Indication: HBV

Selonsertib (ASK-1 inhibitor)
Potential Indication: NASH

Selonsertib (ASK-1 inhibitor)
Potential Indication: Alcoholic Hepatitis

GS-9674 (FXR agonist)
Potential Indication: NASH

GS-9674 (FXR agonist)
Potential Indication: Primary Biliary Cirrhosis

GS-9674 (FXR agonist)
Potential Indication: Primary Sclerosing Cholangitis

GS-0976 (ACC Inhibitor)
Potential Indication: NASH

Despite important scientific progress, cancer remains a leading cause of death worldwide. In both blood cancers and solid tumors, there is an urgent need for new treatments that offer longer remissions, improved survival rates and fewer side effects.

Gilead is exploring novel therapeutics, including combinations of investigational agents, for a range of cancers, with a goal of providing effective new treatment options with favorable safety profiles.

Hematology / Oncology

Phase 1
Phase 2
Phase 3

Axicabtagene ciloleucel (EU Regulatory Submission)
Trial: ZUMA-1
Potential Indication: DLBCL, PMBCL & TFL

Axicabtagene ciloleucel
Trial: ZUMA-5
Potential Indication: Indolent NHL

Axicabtagene ciloleucel
Trial: ZUMA-6
Potential Indication: DLBCL (PD-L1 mAb)

KTE-C19
Trial: ZUMA-2
Potential Indication: MCL

KTE-C19
Trial: ZUMA-3
Potential Indication: Adult ALL

KTE-C19
Trial: ZUMA-4
Potential Indication: Pediatric ALL

KITE-585 (anti-BCMA)
Potential Indication: MM

KITE-718 (MAGE A3/A6)
Potential Indication: Solid Tumor

Idelalisib (PI3K delta inhibitor)
Potential Indication: Relapsed Refractory CLL

Andecaliximab (MMP9 mAb inhibitor)
Potential Indication: Gastric Cancer

Andecaliximab (MMP9 mAb inhibitor)
Potential Indication: Solid Tumors

Entospletinib (Syk inhibitor)
Potential Indication: Hematological Malignancies

Entospletinib (Syk inhibitor)
Potential Indication: Acute Myeloid Leukemia

Tirabrutinib (BTK inhibitor)
Potential Indication: B-cell malignancies

GS-5829 (BET inhibitor)
Potential Indication: Solid Tumors

Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders. We believe that combination regimens targeting multiple pathways have the potential to improve patient outcomes

Inflammation / Respiratory

Phase 1
Phase 2
Phase 3

Filgotinib (JAK1 inhibitor)
Potential Indication: Rheumatoid Arthritis

Filgotinib (JAK1 inhibitor)
Potential Indication: Crohn's Disease

Filgotinib (JAK1 inhibitor)
Potential Indication: Ulcerative Colitis

Filgotinib (JAK1 inhibitor)
Potential Indication: Inflammatory Diseases

Presatovir (fusion inhibitor)
Potential Indication: Respiratory Syncytial Virus 

Entospletinib (Syk inhibitor)
Potential Indication: Chronic Graft Versus Host Disease 

GS-9876 (Syk inhibitor)
Potential Indication: Sjogren’s Syndrome

GS-9876 (Syk inhibitor)
Potential Indication: Lupus

Gilead is collaborating with US Department of Defense, Centers for Disease Control and Prevention and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases. A Gilead investigational agent is currently being studied in Ebola survivors.

Other

Phase 1
Phase 2
Phase 3

GS-5734 (Nuc inhibitor)
Potential indication: Ebola Virus Infection